PALO ALTO, Calif.--(BUSINESS WIRE)--April 5, 2000-- Varian Medical Systems (NYSE: VAR) today announced the appointment of Crisanto Raimundo to corporate controller. Raimundo, 52, has been serving as operations controller for the company for the last six months. He will continue to report to Elisha Finney, vice president and chief financial officer for the company. Raimundo is replacing Duane Walstrom who has elected to leave the company to pursue other interests.
"Cris Raimundo brings extensive experience in both corporate and business unit finance to the position of corporate controller for this company," said Finney. "He is a strong member of our corporate finance team."
Raimundo joined Varian Associates in 1979 and continued to work with the company following its conversion to a stand-alone medical business through the successful spin-off of the semiconductor equipment and instruments businesses on April 2, 1999. He has held several business unit and corporate finance positions, working as a business unit controller, manager of corporate financial analysis and planning, and director of corporate audit. He was serving as controller for the company's oncology systems business until his recent appointment as operations controller for the company.
Raimundo earned his MBA at the University of the Philippines and a BS in accounting and finance at San Beda College in the Philippines. He is a resident of Fremont.
Varian Medical Systems, Inc., (NYSE:VAR) of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X-ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 2,300 people who are located at manufacturing sites in North America and Europe and in its 40 sales and support offices around the world. In its most recent fiscal year ended October 1, 1999, Varian Medical Systems reported sales of $590 million. Additional information is available on the company's investor relations web site at www.varian.com
CONTACT: Varian Medical Systems
Spencer Sias, 650/424-5782